Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: A population-based study from a well-defined geographic region

Leukemia and Lymphoma

Volumn 55, Issue 8, 2014, Pages 1774-1780

  Eketorp Sylvan, Sandra ^a,b   Hansson, Lotta ^a,b   Karlsson, Claes ^a,b   Norin, Stefan ^a,b   Lundin, Jeanette ^a,b   Österborg, Anders ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CLL; Fludarabine refractory; Survival; Time to treatment failure

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; IDARUBICIN; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; FOLLOW UP; HEALTH SURVEY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; REGISTER; SWEDEN;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PUBLIC HEALTH SURVEILLANCE; REGISTRIES; SALVAGE THERAPY; SWEDEN; TREATMENT OUTCOME; VIDARABINE;

EID: 84904876762     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.827786     Document Type: Article

References (21)

1. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.
2. Eichhorst B F, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
3. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088.
4. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
5. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
6. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
7. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007; 48: 1931-1939.
8. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
9. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-1755.
10. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-1574.
11. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as firstline treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773
12. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
13. Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408-2416.
14. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033-2039.
15. Reynolds C, Di Bella N, Lyons RM, et al. A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012; 30: 1232-1240.
16. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
17. Hallek M, Cheson B D, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
18. Fornecker L-M, Aurran-Schleinitz T, Michallet A-S, et al. Salvage therapies in patients with high-risk relapse after fludarabine, cyclophosphamide, rituximab (FCR) for chronic lymphocytic leukemia: the French CLL intergroup experience. Blood 2012; 120(Suppl. 1): Abstract 1796.
19. Nabhan C, Aschebrook-Kilfoy B, Evens A, et al. The impact of race, age, and sex in chronic lymphocytic leukemia (CLL): a comprehensive SEER analysis in the pre and post rituximab (R) eras. Blood 2012; 120(Suppl.): Abstract 2877.
20. Kristinsson SY, Dickman PW, Wilson WH, et al. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica 2009; 94: 1259-1265.
21. Cramer P, Isfort S, Bahlo J, et al. The use of chemoimmunotherapy improves the outcome of patients with chronic lymphocytic leukaemia (CLL) - a metaanalysis of five trials of the German CLL study group (GCLLSG). Blood 2012; 120(Suppl. 1): Abstract 3969.